Physician profile
Dana Vered
NPI 1568935468
$10,411.61
in general payments reported to CMS, 2019-2025
26 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 99% of Licensed Practical Nurse providers received nationally (typical 2025 total: $38.94).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $1,255 · 2023: $2,101 · 2024: $3,258 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,028 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,027.71 |
| Education | $245.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,887.85 | 2021-2025 | |
| Incyte Corporation | $1,161.28 | 2021-2025 | Opzelura |
| Genzyme Corporation | $1,070.72 | 2021-2025 | |
| Janssen Biotech, INC. | $866.15 | 2022-2024 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $827.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $723.50 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $483.31 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $472.18 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $462.59 | 2021-2025 | Sotyktu |
| Lilly USA, LLC | $420.13 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $353.17 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $311.30 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $281.54 | 2022-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $183.45 | 2025 | Nemluvio, Aklief |
| Organon LLC | $175.69 | 2023-2025 | Hadlima, Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $165.16 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $134.04 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.69 | 2023-2025 | Spevigo |
| Revance Therapeutics, INC. | $63.09 | 2024 | Daxxify |
| Stemline Therapeutics INC. | $60.53 | 2021 | |
| Fresenius Kabi USA, LLC | $41.48 | 2023 | Idacio |
| Boston Scientific Corporation | $41.09 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Verrica Pharmaceuticals INC. | $38.25 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $27.73 | 2021-2025 | |
| Epi Health, LLC | $22.23 | 2022 | |
| Journey Medical Corporation | $21.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Vered listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.